Criteria for Full Waivers

• No meaningful therapeutic benefit over existing treatment and not likely to be used in a substantial number of pediatric patients
• Studies are impossible or highly impractical to conduct
• Evidence the product would be unsafe or ineffective in pediatrics

Previous slide

Next slide

Back to first slide

View graphic version